**M3 Literature Review**

**Period: Start date – 05/10/2023**

[Scientific Highlights: 1](#_Toc143520007)

[Clostridioides difficile/ Clostridium difficile 3](#_Toc143520008)

[Fidaxomicin & Clostridium difficile 4](#_Toc143520009)

[Clostridioides difficile vaccine 4](#_Toc143520010)

[Vancomycin & CDI 4](#_Toc143520011)

[CDI 4](#_Toc143520012)

[FMT/ Fecal Microbiota Transplant 5](#_Toc143520013)

[Competitors 5](#_Toc143520014)

[CDAD 6](#_Toc143520015)

[CMC 6](#_Toc143520016)

[Guidelines 6](#_Toc143520017)

[Non-toxigenic C. difficile 6](#_Toc143520018)

[MGB 6](#_Toc143520019)

[Other news of possible interest 7](#_Toc143520020)

Scientific Highlights:

1. CLINICAL OUTCOME AND SEVERITY OF CLOSTRIDIOIDES (CLOSTRIDIUM) DIFFICILE INFECTION AT A TERTIARY REFERRAL HOSPITAL IN BRAZIL.
2. Microbial ecology between Clostridioides difficile and gut microbiota.
3. Clostridioides difficile infection in the allogeneic hematopoietic cell transplant recipient.
4. Microbiome profile and calprotectin levels as markers of risk of recurrent Clostridioides difficile infection.
5. Two Times Versus Four Times Daily Cephalexin Dosing for the Treatment of Uncomplicated Urinary Tract Infections in Females.
6. Effects of fecal microbiota transplantation for recurrent Clostridium difficile infection in children on kidney replacement therapy: a pilot study.
7. Antisense inhibition of RNA polymerase Î± subunit of Clostridioides difficile.
8. Outcomes of high-dose oral beta-lactam definitive therapy compared to fluoroquinolone or trimethoprim-sulfamethoxazole oral therapy for bacteremia secondary to a urinary tract infection.
9. Swiss expert opinion: current approaches in faecal microbiota transplantation in daily practice.
10. Atypical presentation of a rare disorder; idiopathic myointimal hyperplasia of mesenteric veins (IMHMV): Report of two cases.
11. Biofilm Formation of Clostridioides difficile, Toxin Production and Alternatives to Conventional Antibiotics in the Treatment of CDI.
12. Prevalence of Non-Toxigenic Clostridioides difficile in Diarrhoea Patients and Their Clinical Characteristics.
13. Safety and tolerability of frozen, capsulized autologous faecal microbiota transplantation. A randomized double blinded phase I clinical trial.
14. The Intestinal Microbiome and the Metabolic Syndrome-How Its Manipulation May Affect Metabolic-Associated Fatty Liver Disease (MAFLD).
15. Clostridium scindens secretome suppresses virulence gene expression of Clostridioides difficile in a bile acid-independent manner.
16. Correlation between the presence of a cecal appendix and reduced diarrhea severity in primates: new insights into the presumed function of the appendix.
17. Short-course empiric antibiotics in children undergoing allogeneic hematopoietic cell transplant.
18. Long-term Safety Outcomes of Fecal Microbiota Transplantation: Real-World Data over Eight Years from the Hong Kong FMT Registry.
19. A Potent and Narrow-Spectrum Antibacterial against Clostridioides difficile Infection.
20. Novel, non-colonizing, single-strain live biotherapeutic product ADS024 protects against Clostridioides difficile infection challenge in vivo.

Clostridioides difficile/ Clostridium difficile

1. Asymmetric Contribution of a Selectivity Filter Gate in Triggering Inactivation of Ca (V) 1.3 Channels.
2. Facile synthesis of a new covalent organic nanosheet (CON-KEY1) based on polyamide links as an effective heterogeneous catalyst in C-C cross coupling reactions.
3. Controllable Preparation of a N-Doped Hierarchical Porous Carbon Framework Derived from ZIF-8 for Highly Efficient Capacitive Deionization.
4. Interdisciplinary Spanish consensus on a watch-and-wait approach for rectal cancer.
5. HRMAS (13) C NMR and genome-scale metabolic modeling identify threonine as a preferred dual redox substrate for Clostridioides difficile.
6. Genomic epidemiology of Clostridioides difficile in individuals admitted to an intensive care unit.
7. An integrated pipeline for prediction of Clostridioides difficile infection.
8. Water resource sustainable use assessment methodology and an impact factor analysis framework for SDG 6-oriented river basins: evidence from the Yellow River basin (Shaanxi section) in China.
9. Evaluating outpatient diagnostic stewardship of comprehensive polymerase chain reaction Clostridioides difficile testing in a regional health system.

Fidaxomicin & Clostridium difficile

1. The Role of Fecal Microbiota Transplantation in the Allogeneic Stem Cell Transplant Setting.
2. Clostridioides difficile Infection: Landscape and Microbiome Therapeutics.
3. CE: Current and Emerging Applications of Fecal Microbiota Transplantation.
4. Patient Perception of Route of Rectal Administration of Live Biotherapeutic Product for Recurrent Clostridioides difficile Infection.
5. Clostridioides difficile Infection in Pediatric Inflammatory Bowel Disease.
6. Identification of donor Bacteroides vulgatus genes encoding proteins that correlate with early colonization following fecal transplant of patients with recurrent Clostridium difficile.
7. Systems-ecology designed bacterial consortium protects from severe Clostridioides difficile infection.
8. Therapeutics for Clostridioides difficile infection: molecules and microbes.
9. Recurrent Multidrug-Resistant Clostridium difficile Infection Secondary to Ulcerative Colitis a Case Report.
10. Effectiveness of Fecal Microbiota Transplantation Treatment in Patients With Recurrent Clostridium difficile Infection, Ulcerative Colitis, and Crohn's Disease: A Systematic Review.
11. Gut microbiome and its clinical implications: exploring the key players in human health.

Clostridioides difficile vaccine

1. Mining Autoimmune-Disorder-Linked Molecular-Mimicry Candidates in Clostridioides difficile and Prospects of Mimic-Based Vaccine Design: An In Silico Approach.
2. Infectious complications in patients with inflammatory bowel disease in Asia: the results of a multinational web-based survey in the 8th Asian Organization for Crohn's and Colitis meeting.
3. A Phase 2 Extension Study Evaluating the Immunogenicity, Safety, and Tolerability of 3 or 4 Doses of a Clostridioides difficile Vaccine in Healthy US Adults 65 to 85 Years of Age.
4. Recurrent Clostridioides difficile Infection: Current Clinical Management and Microbiome-Based Therapies.
5. A Young Adult With Multisystem Inflammatory Syndrome Following Weeks of Initial COVID-19 Respiratory Infection, With No Prior COVID-19 Vaccination: A Case Report.
6. COVID-19 booster vaccination during pregnancy enhances maternal binding and neutralizing antibody responses and transplacental antibody transfer to the newborn.
7. Colon Cancer Risk Following Intestinal Clostridioides difficile Infection: A Longitudinal Cohort Study.
8. Oligomerization and Adjuvant Activity of Peptides Derived from the VirB4-like ATPase of Clostridioides difficile.
9. Lessons from a COVID-19 outbreak in the disability support sector, Australian Capital Territory, August 2021.
10. Evolving epidemiology of Q fever in Wide Bay.
11. Australian National Enterovirus Reference Laboratory annual report, 2022.
12. Increased intestinal permeability and downregulation of absorptive ion transporters Nhe3, Dra, and Sglt1 contribute to diarrhea during Clostridioides difficile infection.
13. Vaccination is an integral strategy to combat antimicrobial resistance.
14. Vaccine Preventable Diseases and Vaccination Coverage in Aboriginal and Torres Strait Islander People, Australia, 2016-2019.
15. A Comparison of Pathogen Detection and Risk Factors among Symptomatic Children with Gastroenteritis Compared with Asymptomatic Children in the Post-rotavirus Vaccine Era.
16. [Clostridioides difficile - New Insights and Therapy Recommendations].
17. Optimizing the Production of gp145, an HIV-1 Envelope Glycoprotein Vaccine Candidate and Its Encapsulation in Guanosine Microparticles.
18. Mucosal Vaccination Strategies against Clostridioides difficile Infection.
19. Critical Damage of Lung Parenchyma Complicated with Massive Pneumothorax in COVID-19 Pneumonia.
20. Host Immunity and Immunization Strategies for Clostridioides difficile Infection.

Vancomycin & CDI

1. In vivo evaluation of Clostridioides difficile enoyl-ACP reductase II (FabK) Inhibition by phenylimidazole unveils a promising narrow-spectrum antimicrobial strategy.
2. When less is more: shortening the Lpp protein leads to increased vancomycin resistance in Escherichia coli.
3. A US-based national surveillance study for the susceptibility and epidemiology of Clostridioides difficile isolates with special reference to ridinilazole: 2020-2021.
4. Evaluation of the effectiveness and safety of oral vancomycin versus placebo in the prevention of recurrence of Clostridioides difficile infection in patients under systemic antibiotic therapy: a phase III, randomised, double-blind clinical trial.
5. Incidence and risk factors for recurrent Clostridioides difficile infection in pediatric at-risk groups in selected Pediatric Investigators Collaborative Network on Infections in Canada (PICNIC) hospitals.
6. Clostridioides difficile Infection in Inflammatory Bowel Disease Patients: A Systematic Review of Risk Factors and Approach in Management.
7. Effectiveness of ultraviolet-C disinfection systems for reduction of multi-drug resistant organism infections in healthcare settings: A systematic review and meta-analysis.
8. Design, Synthesis and Biological Evaluation of Novel PEG-Rakicidin B1 Hybrid as Clostridium difficile (CD) Targeted Anti-Bacterial Agent.
9. Clinical Efficacy of Fidaxomicin and Oral Metronidazole for Treating Clostridioides difficile Infection and the Associated Recurrence Rate: A Retrospective Cohort Study.

CDI

1. Evaluation of an Empiric Vancomycin Dosing Protocol on Goal Troughs and Acute Kidney Injury in a Neonatal Intensive Care Unit.
2. Bimetal-oxide (Fe/Co) modified bagasse-waste carbon coated on lead oxide-battery electrode for metronidazole removal.
3. A protein-free vaccine stimulates innate immunity and protects against nosocomial pathogens.
4. O antigen biogenesis sensitises Escherichia coli K-12 to bile salts, providing a plausible explanation for its evolutionary loss.
5. EFFICACY AND SAFETY OF GEMIFLOXACIN CONTAINING TREATMENT REGIMEN IN FIRST-LINE TREATMENT OF HELICOBACTER PYLORI.
6. The pharmacokinetics and pharmacodynamics of continuous infusion vancomycin in adult people with cystic fibrosis.
7. Are enterococcal bloodstream infections an independent risk factor for a poorer 5-year survival or just a marker for severity of illness?-The Munich multicentric enterococci cohort.
8. Incidence of Central Line-Associated Bloodstream Infection in a Tertiary Care Hospital in Northern India: A Prospective Study.
9. Osmotic Demyelination Syndrome in a Normonatremic Patient Under Treatment With Proton Pump Inhibitors.
10. Partnering essential oils with antibiotics: proven therapies against bovine Staphylococcus aureus mastitis.
11. Case report: Successful treatment of recurrent E. coli infection with bacteriophage therapy for patient suffering from chronic bacterial prostatitis.
12. Invasive Sinusitis With Arcanobacterium haemolyticum and Fusobacterium necrophorum Complicated by Subdural Empyema in an Immunocompetent Adolescent Patient.
13. Tigecycline Tango: A Case of Antibiotic-Induced Pancreatitis.
14. Community-associated methicillin-resistant Staphylococcus aureus infection of diabetic foot ulcers in an eastern diabetic foot center in a tertiary hospital in China: a retrospective study.
15. Bioequivalence Evaluation of Topical Metronidazole Products Using Dermal Microdialysis in New Zealand Rabbits.
16. Transient reactive phlebitis and intravenous ciprofloxacin: Is there an association?

FMT/ Fecal Microbiota Transplant

1. The Role of Fecal Microbiota Transplantation in the Allogeneic Stem Cell Transplant Setting.
2. Clostridioides difficile Infection: Landscape and Microbiome Therapeutics.
3. CE: Current and Emerging Applications of Fecal Microbiota Transplantation.
4. Patient Perception of Route of Rectal Administration of Live Biotherapeutic Product for Recurrent Clostridioides difficile Infection.
5. Clostridioides difficile Infection in Pediatric Inflammatory Bowel Disease.
6. Identification of donor Bacteroides vulgatus genes encoding proteins that correlate with early colonization following fecal transplant of patients with recurrent Clostridium difficile.
7. Systems-ecology designed bacterial consortium protects from severe Clostridioides difficile infection.
8. Therapeutics for Clostridioides difficile infection: molecules and microbes.
9. Recurrent Multidrug-Resistant Clostridium difficile Infection Secondary to Ulcerative Colitis a Case Report.
10. Effectiveness of Fecal Microbiota Transplantation Treatment in Patients With Recurrent Clostridium difficile Infection, Ulcerative Colitis, and Crohn's Disease: A Systematic Review.
11. Gut microbiome and its clinical implications: exploring the key players in human health.

Competitors

1. Impact of antibiotic pharmacokinetics in urine on recurrent bacteriuria following treatment of complicated urinary tract infections.
2. Primary Feline Tauopathy: Clinical, Morphological, Immunohistochemical, and Genetic Studies.
3. Regional changes in intestinal permeability in cirrhosis are associated with mucosal bacteria.
4. Literature review on the potential of urban waste for the fertilization of urban agriculture: A closer look at the metropolitan area of Barcelona.
5. In vitro activity of new combinations of Î²-lactam and Î²-lactamase inhibitors against the Mycobacterium tuberculosis complex.
6. The In vitro activity of carbapenems alone and in combination with Î²-lactamase inhibitors against difficult-to-treat mycobacteria; Mycobacterium tuberculosis, Mycobacterium abscessus, and Mycobacterium avium complex: A systematic review.
7. Transcriptional repression during spermatogenesis in C. elegans requires TOP-2, condensin II, and the MET-2 H3K9 methyltransferase.
8. Two-year durability of REBYOTAâ„¢ (RBL), a live biotherapeutic for the prevention of recurrent Clostridioides difficile infections.
9. The in vitro effect of new combinations of carbapenem-Î²-lactamase inhibitors for Mycobacterium abscessus.
10. Microplastics influence on herbicides removal and biosurfactants production by a Bacillus sp. strain active against Fusarium culmorum.
11. Impact of acquired broad-spectrum Î²-lactamases on susceptibility to oral penems/carbapenems (tebipenem, sulopenem, and faropenem) alone or in combination with avibactam and taniborbactam Î²-lactamase inhibitors in Escherichia coli.
12. Efficacy of Bezlotoxumab Against Clostridioides difficile Infection: A Case-Series Study at a University Hospital in Japan and Literature Review.
13. Key patient demographics shape innate immune topography in noncritical hypoxic COVID-19 pneumonia.
14. Metformin and exercise effects on postprandial insulin sensitivity and glucose kinetics in pre-diabetic and diabetic adults.

CDAD

1. ANTIDEPRESSANT MEDICATIONS ARE ASSOCIATED WITH INCREASED RISK OF HOSPITAL-ACQUIRED CLOSTRIDIOIDES DIFFICILE INFECTION: A POPULATION-BASED STUDY.
2. Diagnosis and treatment of "chronic Lyme": primum non nocere.
3. Isofagomine inhibits multiple TcdB variants and protects mice from Clostridioides difficile induced mortality.
4. Phage therapy in gut microbiome.
5. Association of Clostridioides difficile infection rates with social determinants of health in Denver area census tracts, 2016-2019.
6. A Multifaced Aspect of Clostridium difficile Infection in Pediatric Patients with Inflammatory Bowel Disease: Case Series and Literature Review.
7. The Interaction between the Host Genome, Epigenome, and the Gut-Skin Axis Microbiome in Atopic Dermatitis.
8. Glycine fermentation by C. difficile promotes virulence and spore formation, and is induced by host cathelicidin.
9. Exploring the inhibitory potential of the antiarrhythmic drug amiodarone against Clostridioides difficile toxins TcdA and TcdB.
10. The TcdE holin drives toxin secretion and virulence in Clostridioides difficile.
11. Incidence and clinical relevance of postoperative diarrhea after minimally invasive gastrectomy for gastric cancer: a single institution retrospective study of 1476 patients.

CMC

1. Manufacturing Processes of a Purified Microbiome Therapeutic Reduce Risk of Transmission of Potential Bacterial Pathogens in Donor Stool.
2. MRI Apparent Diffusion Coefficient (ADC) as a Biomarker of Tumour Response: Imaging-Pathology Correlation in Patients with Hepatic Metastases from Colorectal Cancer (EORTC 1423).
3. A microbial consortium alters intestinal Pseudomonadota and antimicrobial resistance genes in individuals with recurrent Clostridioides difficile infection.
4. [Fecal Microbiota Transfer (FMT) in Germany - Status and Perspective].
5. Unlocking Enhanced Capacitive Deionization of NaTi(2)(PO(4))(3)/Carbon Materials by the Yolk-Shell Design.
6. Novel Biomarkers, Including tcdB PCR Cycle Threshold, for Predicting Recurrent Clostridioides difficile Infection.
7. Particle size optimization of metal-organic frameworks for superior capacitive deionization in oxygenated saline water.
8. Structural Basis for Binding of Neutralizing Antibodies to Clostridioides difficile Binary Toxin.
9. Effect of Mannan-rich fraction supplementation on commercial broiler intestinum tenue and cecum microbiota.
10. Effect of Selective Decontamination of the Digestive Tract on Hospital Mortality in Critically Ill Patients Receiving Mechanical Ventilation: A Randomized Clinical Trial.
11. Manufacturing Process of SER-109, a Purified Investigational Microbiome Therapeutic, Reduces Risk of Coronavirus Transmission From Donor Stool.
12. SER-109: An Oral Investigational Microbiome Therapeutic for Patients with Recurrent Clostridioides difficile Infection (rCDI).
13. Effectiveness and Safety of Colonic and Capsule Fecal Microbiota Transplantation for Recurrent Clostridioides difficile Infection.
14. [Fecal microbiota transplantation: indications, risks and opportunities].
15. Development of a New Additive Based on Textile Fibers of End-of-Life Tires (ELT) for Sustainable Asphalt Mixtures with Improved Mechanical Properties.
16. Design and manufacture of a lyophilised faecal microbiota capsule formulation to GMP standards.
17. Validation of Clinical Risk Models for Clostridioides difficile-Attributable Outcomes.
18. Comparative Evaluation of Three Immunoassays for the Simultaneous Detection of Clostridioides difficile Glutamate Dehydrogenase and Toxin A/B.
19. Occurrence of Rotavirus A Genotypes and Other Enteric Pathogens in Diarrheic Suckling Piglets from Spanish Swine Farms.

Guidelines

1. The effect of circadian preference and sleep disturbances on depression in children 6 to 12 years of age.
2. Clostridioides Difficile in Latin America: An Epidemiological Overview.
3. Clostridioides (Clostridium) difficile: A silent nosocomial pathogen.
4. Reducing antimicrobial overuse through targeted therapy for patients with community-acquired pneumonia: a study protocol for a cluster-randomized factorial controlled trial (CARE-CAP).
5. Budesonide, an anti-inflammatory drug, exacerbate clostridioides difficile colitis in mice.
6. Syndromic Panel Testing Among Patients With Infectious Diarrhea: The Challenge of Interpreting Clostridioides difficile Positivity on a Multiplex Molecular Panel.
7. Absence of anti-rabphilin-3A antibodies in children and young adults with idiopathic central diabetes insipidus: a potential clue to elucidating a tumor etiology.
8. Fecal Microbiota Transplantation in Human Immunodeficiency Virus-Infected Patient Population: A Systematic Review and Meta-Analysis.
9. The Effect of Antibiotic Therapy for Clostridioides difficile Infection on Mortality and Other Patient-Relevant Outcomes: a Systematic Review and Meta-analysis.
10. Washed microbiota transplantation for Clostridioides difficile infection: a national multi-center real-world study.
11. Prevalence of Clostridioides difficile contamination in the healthcare environment and instruments: A systematic review and meta-analysis.
12. Inhibition of selenoprotein synthesis is not the mechanism by which auranofin inhibits growth of Clostridioides difficile.
13. Individualized antibiotic plans as a quality improvement initiative to reduce carbapenem use for hematopoietic cell transplant patients at a freestanding pediatric hospital.
14. Clostridioides difficile resistance to antibiotics, including post-COVID-19 data.
15. Next Steps in Ambulatory Stewardship.
16. A Digital Counselor-Delivered Intervention for Substance Use Among People With HIV: Development and Usability Study.

Non-toxigenic C. difficile

1. Novel ribotype/sequence type associations and diverse CRISPR-Cas systems in environmental Clostridioides difficile strains from Northern Iraq.
2. A local-scale One Health genomic surveillance of Clostridioides difficile demonstrates highly related strains from humans, canines, and the environment.
3. Clostridioides (Clostridium) difficile in adults with diarrhoea in Vietnam.
4. [Study on the features of Clostridioides difficile infection among diarrhea patients in Kunming from 2018 to 2020].
5. Membrane Vesicles of Toxigenic Clostridioides difficile Affect the Metabolism of Liver HepG2 Cells.
6. Draft Genome Sequences and Genome Characterization of Three Toxigenic and Two Nontoxigenic Clostridioides difficile Clinical Isolates from Florida, USA.
7. VE303, a Defined Bacterial Consortium, for Prevention of Recurrent Clostridioides difficile Infection: A Randomized Clinical Trial.
8. Clostridioides difficile in food and food products of animal origin in Assam, India.
9. Laboratory diagnosis of Clostridioides difficile infection in symptomatic patients: what can we do better?
10. Non-Toxigenic Clostridioides difficile Strain E4 (NTCD-E4) Prevents Establishment of Primary C. difficile Infection by Epidemic PCR Ribotype 027 in an In Vitro Human Gut Model.
11. Effective Colonization by Nontoxigenic Clostridioides difficile REA Strain M3 (NTCD-M3) Spores following Treatment with Either Fidaxomicin or Vancomycin.
12. Clostridioides difficile aggravates dextran sulfate solution (DSS)-induced colitis by shaping the gut microbiota and promoting neutrophil recruitment.
13. A rapid multiplex real-time PCR detection of toxigenic Clostridioides difficile directly from fecal samples.
14. Molecular epidemiology of Clostridioides difficile in companion animals: Genetic overlap with human strains and public health concerns.
15. Prevalence, Antimicrobial Resistance and Toxin-Encoding Genes of Clostridioides difficile from Environmental Sources Contaminated by Feces.
16. Comparative biofilm-forming ability between Clostridioides difficile strains isolated in Latin America and the epidemic NAP1/027 strain.
17. Accuracy of diagnostic assays for the detection of Clostridioides difficile: A systematic review and meta-analysis.
18. Frequency of Diarrhea, Stool Specimen Collection and Testing, and Detection of Clostridioides Difficile Infection Among Hospitalized Adults in the Muenster/Coesfeld Area, Germany.

MGB

1. Liposomal Epigallocatechin-3-Gallate for the Treatment of Intestinal Dysbiosis in Children with Autism Spectrum Disorder: A Comprehensive Review.
2. Short-chain fatty and carboxylic acid changes associated with fecal microbiota transplant communally influence microglial inflammation.
3. Redefining Clostridioides difficile infection antibiotic response and clinical outcomes.
4. [Fecal Microbiota Transplants in the Context of (Child and Adolescent) Psychiatric Disorders].
5. Antibiotic-Therapy-Induced Gut Dysbiosis Affecting Gut Microbiota-Brain Axis and Cognition: Restoration by Intake of Probiotics and Synbiotics.
6. The Urgent Threat of Clostridioides difficile Infection: A Glimpse of the Drugs of the Future, with Related Patents and Prospects.
7. The Role of Fecal Microbiota Transplantation in the Treatment of Neurodegenerative Diseases: A Review.
8. Insights into the Spectrum of Activity and Mechanism of Action of MGB-BP-3.
9. Metabolic Phenotyping Study of Mouse Brain Following Microbiome Disruption by C.difficile Colonization.
10. Efficacy and Safety of RBX2660 in PUNCH CD3, a Phase III, Randomized, Double-Blind, Placebo-Controlled Trial with a Bayesian Primary Analysis for the Prevention of Recurrent Clostridioides difficile Infection.
11. Extended Follow-up of Microbiome Therapeutic SER-109 Through 24 Weeks for Recurrent Clostridioides difficile Infection in a Randomized Clinical Trial.
12. Ion Exchange Conversion of Na-Birnessite to Mg-Buserite for Enhanced and Preferential Cu(2+) Removal via Hybrid Capacitive Deionization.
13. Clostridioides difficile and neurological disorders: New perspectives.
14. Pain and Opioid-Induced Gut Microbial Dysbiosis.
15. Fecal microbiota transplantation can improve cognition in patients with cognitive decline and Clostridioides difficile infection.
16. Fecal Microbiota Transplantation as New Therapeutic Avenue for Human Diseases.
17. An update on fecal microbiota transplantation for the treatment of gastrointestinal diseases.
18. The use of Faecal Microbiota Transplantation (FMT) in Europe: A Europe-wide survey.
19. Guidelines for reporting on animal fecal transplantation (GRAFT) studies: recommendations from a systematic review of murine transplantation protocols.
20. Cognitive function improvement after fecal microbiota transplantation in Alzheimer's dementia patient: a case report.